by RNA Diagnostics | Jun 14, 2017 | Uncategorized
Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will...
by RNA Diagnostics | Sep 15, 2016 | Uncategorized
A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant...
by RNA Diagnostics | Apr 1, 2016 | Uncategorized
Rna Diagnostics Inc. appoints Dr. Jeremy Bridge-Cook President and CEO Dr. Ken Pritzker, on behalf of the Board of Directors of Rna Diagnostics Inc., is pleased to announce the appointment of Dr. Jeremy Bridge-Cook to the position of President and Chief Executive...
by RNA Diagnostics | Mar 10, 2016 | Uncategorized
Rna Diagnostics announces the publication of a study on February 24 2016 in the journal BMC Cancer entitled RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. The study concludes that RNA disruption, as assessed...
by RNA Diagnostics | Feb 18, 2016 | Uncategorized
Rna Diagnostics Inc. announced today that Paul Lucas, an accomplished veteran of the Life Sciences industry, has joined the Company’s Board of Directors. “Paul brings a wealth of proven business and Life Science innovation insight to Rna Diagnostics,” said Dr. Ken...
